Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 0.79 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709534 | 0.93 | PDE10A (0.86) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL15134970 | 0.91 | PDE10A (0.84) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2630828 | 0.91 | PDE10A (1.00) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2631107 | 0.89 | PDE10A (1.00) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2630790 | 0.88 | PDE10A (0.82) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2631097 | 0.88 | PDE10A (0.80) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2630924 | 0.88 | PDE10A (0.78) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2630896 | 0.87 | PDE10A (0.77) | PDE10A | |
| SCHEMBL2595779 | 0.87 | PDE10A (1.00) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL2631032 | 0.85 | PDE10A (0.74) | PDE10APDE2APDE1BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | claimed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | claimed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 14/4885PDE1B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.